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Karonudib has potent anti‑tumor 
effects in preclinical models 
of B‑cell lymphoma
Morten P. Oksvold1,2, Ulrika Warpman Berglund3, Helge Gad3,4, Baoyan Bai1,2, Trond Stokke5, 
Idun Dale Rein5, Therese Pham3, Kumar Sanjiv3, Geir Frode Øy6, Jens Henrik Norum7, 
Erlend B. Smeland1,2, June H. Myklebust1,2, Thomas Helleday3,4 & Thea Kristin Våtsveen1,2* 
Chemo‑immunotherapy has improved survival in B‑cell lymphoma patients, but refractory/relapsed 
diseases still represent a major challenge, urging for development of new therapeutics. Karonudib 
(TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP‑incorporation in 
DNA. MTH1 is highly upregulated in tumor biopsies from patients with diffuse large B‑cell lymphoma 
(DLBCL) and Burkitt lymphoma, hence confirming a rationale for targeting MTH1. Here, we tested 
the efficacy of karonudib in vitro and in preclinical B‑cell lymphoma models. Using a range of B‑cell 
lymphoma cell lines, karonudib strongly reduced viability at concentrations well tolerated by 
activated normal B cells. In B‑cell lymphoma cells, karonudib increased incorporation of 8‑oxo‑dGTP 
into DNA, and prominently induced prometaphase arrest and apoptosis due to failure in spindle 
assembly. MTH1 knockout cell lines were less sensitive to karonudib‑induced apoptosis, but were 
displaying cell cycle arrest phenotype similar to the wild type cells, indicating a dual inhibitory role of 
the drug. Karonudib was highly potent as single agent in two different lymphoma xenograft models, 
including an ABC DLBCL patient derived xenograft, leading to prolonged survival and fully controlled 
tumor growth. Together, our preclinical findings provide a rationale for further clinical testing of 
karonudib in B‑cell lymphoma.
The use of chemo-immunotherapy has greatly improved survival in B-cell lymphoma patients, but relapsed/
refractory disease still remains a prominent clinical challenge. Diffuse large B-cell lymphoma (DLBCL) is the 
most common type of aggressive non-Hodgkin lymphoma and 60–70% of patients are cured with standard 
treatment with R-CHOP1. However, only 10% of patients with relapsed/refractory disease will reach a 3-year 
progression-free  survival2. Burkitt lymphoma (BL) is an aggressive lymphoma and requires intensified chemo-
immunotherapy3, whereas mantle cell lymphoma (MCL) has no standard frontline therapy and is considered 
incurable with current treatment  strategies4.
Karonudib (TH1579) is a novel drug developed to target the nucleotide metabolism by inhibiting the nucleo-
tide pool sanitizing enzyme 7,8-dihydro-8-oxoguanine triphosphatase/MutT-homologue-1 (MTH1), encoded by 
Nudix hydrolase 1 (NUDT1)5. MTH1 converts oxidized nucleotide triphosphates (8-oxo-dGTP6, 2-OH-dATP7 
and O-6-methyl-dGTP8) to the corresponding monophosphate forms. Hence, active MTH1 prevents incorpora-
tion of oxidized nucleotides into DNA, which otherwise could cause mispairing, mutations and ultimately cell 
 death6,9. Under normal conditions with low reactive oxygen species (ROS) burden, MTH1 is not essential for 
cell  survival10. This contrasts cancer cells which frequently upregulate MTH1 to compensate for increased ROS 
with corresponding higher oxidized nucleotide  levels11,12. Furthermore, karonudib has a dual mechanism as it 
also directly and indirectly can perturb microtubule polymerization dynamics via an emerging role of MTH1 in 
 mitosis13,14. Inhibition of MTH1 has potent anti-tumor activity in mouse models of colon cancer, malignant mela-
noma, hepatocellular carcinoma, -lung- and breast  cancer5,15–18. The first in human clinical trial investigation with 
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karonudib treatment has been initiated for patients with advanced solid malignancies (NCT03036228) and acute 
leukemias (NCT04077307); https:// clini caltr ials. gov.
Here, we tested the effect of karonudib in vitro, explored the mechanisms of action and tested the in vivo effi-
cacy of the drug using two different B-cell lymphoma xenograft models. Together, our data demonstrate a potent 
anti-tumor effect of karonudib and argue for its potential clinical use in treatment of aggressive B-cell lymphoma.
Materials and methods
Materials. Karonudib (TH1579) was synthesized in the Helleday laboratory as described  earlier19.
Cell lines, human samples and culture conditions. Burkitt lymphoma  (BL): BL-41, Raji, Ramos, 
Rec-1 (Leibniz-Institut-Deutche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)); Germinal center 
like B-cells (GCB) DLBCL: SU-DHL-6 (DSMZ), SU-DHL-4 (gift from L. Staudt, NCI, USA); Activated B-cell 
like  (ABC) DLBCL: U2932 (DSMZ); DLBCL-double hit: Will-2 (DSMZ); immunoblastic B cell lymphoma: 
DoHH-2 (DSMZ); mantle cell lymphoma (MCL): Mino, JeKo-1, Granta-519 (DSMZ). Cell lines are kept for up 
to 8 weeks and mycoplasma tested with Venor GeM Classic (Minerva BioLabs, Berlin, Germany) after 4 weeks 
and always prior to injection of cells into mice. Cell lines were cultured in RPMI-1640 supplemented with 10% 
human serum (HS; TCS Biosciences, Buckingham, UK) or 10% fetal calf serum (FCS), penicillin and streptomy-
cin, and maintained at 37 °C in 5%  CO2. Cell line authentication was done by PCR-single-locus technology for 
21 independent PCR systems (Eurofins, Denmark).
Peripheral blood was obtained from anonymous, healthy donors at the Blood Bank (Oslo University Hospital, 
Norway), with informed consent and approval from regional authorities, Regional Ethical Committee for Medi-
cal and Health Research Ethics (REK S-03280). Cells were maintained and activated as described  earlier20,21. 
B cells were purified using Dynabeads CD19 Pan B according to manufacturer’s instruction (Thermo Fischer 
Scientific). The B cells were activated minimum 24 h prior to experiments. The BL-41-luc cell line for xenograft 
studies has previously been  described20. Patient derived DFBL-49659-V2 cells were obtained from PRoXe (The 
Public Repository of Xenografts, Dana-Farber Institute of Cancer).
Cell viability, apoptosis, cell cycle analysis and DNA damage. Measurement of relative cell growth 
(CellTiterGlo, 72 h, karonudib (0.0625–1 µM)), viability (propidium iodide, 72 h, karonudib (0.25–1 µM)) and 
apoptosis (Active Caspase-3, 24  h, karonudib (0.5  µM)) was performed as previously  described20. Prolifera-
tion (72 h, karonudib (0.25 µM) was performed using Cell Trace Violet (ThermoFisher Scientific). Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed together with cell cycle analysis 
after 6, 12 and 24 h with karonudib treatment (0.5 µM) as previously  described20,22,23. For cell cycle studies live/
dead cell staining (near-IR dead cell stain kit L10119, Thermo Fisher Scientific) was performed prior to fixa-
tion. Antibodies: rabbit anti-phospho-histone H3 (pS10 #06-570 1:500; Merck), mouse anti-phospho-γ-histone 
H2AX (pS139 clone JWB301, #05-635 1:500; Merck), donkey anti-mouse IgG-Alexa488 (#715-545-150 1:500; 
Jackson Immunoresearch, West Grove, PA), and goat-anti-rabbit IgG-PE (1:500; Thermo). In addition we used 
biotin-16-dUTP (Merck), streptavidin-Cy5 (PA45001 1:400; GE Healthcare, UK) and Hoechst 33258 (2 µg/ml). 
Hoechst stained cells were stored at 4°C over night before analysis. Flow cytometry data were analyzed using the 
online Cytobank flow cytometry software (https:// commu nity. cytob ank. org)24 or FlowJo v10.
Gene expression profiling. Total RNA was isolated (MiRNeasy, Qiagen, Hilden, Germany) after 12  h 
treatment with karonudib (0.5 µM). The microarray analyses were performed on GeneChip Human Gene 2.0 
ST Array (Affymetrix, Santa Barbara, CA). Two replicates were run per cell line (BL-41 and Mino). Gene set 
enrichment analysis was performed using the GSEA software v.3.025,26, combining both cell line data against 
predicted gene sets (Hallmark datasets) downloaded from the MSigDB  collection27. A thousand permutations 
were performed to test against control and karonudib treated cells. Gene sets with false discovery rate (FDR) 
q values < 0.1 were regarded as significantly enriched gene sets. Microarray data is available at NCBI’s Gene 
Expression Omnibus with accession number GSE123449. Publicly available mRNA expression data was used 
from the LLMPP study: Follicular Lymphoma (FL) (n = 191)  GSE5382028, ABC-DLBCL (n = 176)  GSE1084629, 
GCB-DLBCL (n = 97)  GSE1084629, BL (n = 24)  GSE473230 and B-cells from PBMC (n = 5)  GSE4606231. Micro-
dissected samples are from  GSE1245332.
Western immunoblotting. Cells were lysed and processed for SDS-PAGE, and immunoblotting was per-
formed as described  earlier20,33. Antibodies: mouse anti-MTH1 (SC-271082; Santa Cruz Biotechnology, TX), 
rabbit anti-GAPDH (GTX102784; GeneTex, CA), and HRP-conjugated donkey anti-mouse and –rabbit IgG 
(Jackson Immunoresearch). Full immunoblots are displayed in Supplemental Fig. 7.
Modified Comet assay. The modified comet assay has been described  previously5,15. Briefly, BL-41 cells 
were treated with 0.5 µM Karonudib for 24 h and 20 mM KBrO3 for 2 h. Cells were harvested by centrifugation, 
mixed with 1.2% low-melting agarose at 37°C and added to fully-frosted slides (Thermo Fisher Scientific). Cells 
were kept in lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris pH 10.0, 10% DMSO, 1% Triton X-100) at 4°C 
O/N in the dark. To detect 8-oxo-dG lesions, slides were incubated with recombinant 8-oxoguanine DNA glyco-
sylase (OGG-1) (2.0 μg/ml) diluted in enzyme reaction buffer (40 mM HEPES pH 8.0, 0.1 M KCl, 0.5 mM EDTA 
and 0.2 mg/ml BSA) at 37°C for 45 min. Electrophoresis was run at 4°C at 300 mA, 25 V for 30 min. DNA was 
counterstained with SYBR Gold dye (Thermo Fisher Scientific) and images were acquired with a 10× objective 
in a Zeiss IF microscope and quantified using Comet Assay IV software (Instem, UK).
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Gene editing. Gene editing by CRISPR-Cas9 technology was done by electroporation of  validated34 guide 
RNA sequence for MTH1 (CAT GAA AAA GCG AGG CTT CG (Integrated DNA technology)) in Mino-Cas9 cells 
created as previously  described35.
Animal experiments. The care and handling of animals for the present study was approved by the Nor-
wegian Food Safety Authority in compliance with the European Convention of the Protection of Vertebrates 
Used for Scientific Purposes in compliance with the ARRIVE guidelines (Project ID11675). NOD.Cg-Prkdcscid 
 Il2rgtm1Wjl/SzJ (NSG) mice were bred in-house. Based on prior experiments with these mice and BL-41-luc cell 
line, n = 11 for each of treatment and control groups were  chosen20. Mice (6–10 weeks old), were injected sub-
cutaneously with 2 ×  106 BL-41-luc cells. Tumor take was measured by bioluminescent imaging (IVIS spectrum 
in vivo imaging system) after 5 days. The mice were grouped within each cage for either karonudib or control 
based on tumor size in order to have non-biased, comparable groups. The DFBL-49659-V2 ABC DLBCL patient 
derived xenograft (PDX) was established from a patient who relapsed after receiving autologous stem cell trans-
plant. The patient had received several prior treatments, including bortezomib and rituximab, R-CHOP and 
RICE. PDX cells were injected intravenously and treatment started at day 12. Mice were randomized in each 
cage. Pharmacokinetic studies of karonudib have been performed by Berglund et al.5, and the same dosing and 
treatment regiments that were found to be optimal were used in this study. Briefly, karonudib was dissolved in a 
20% (w/v) solution of hydroxypropyl-β-cyclodextrins in acetate buffer (pH 4.6) to a concentration of 9 mg/ml. 
Mice were given karonudib (90 mg/kg) twice a day (b.i.d) by oral gavage three times a week (Monday–Wednes-
day–Friday schedule), until all control animals were euthanized due to tumor size in the BL-41-luc model and 
appearance of clinical signs in the PDX model. Tumor growth was monitored by  IVIS20 or  T2-weighted magnetic 
resonance imaging (MRI) using 7 T MR system (Biospec 70/20 USR, Bruker BioSpin MRI GmbH, Ettlingen, 
Germany) equipped with a volume T/R resonator with 75/40 mm diameter at regular intervals on days with-
out drug administration. The volume of the spleen was measured by manual delineation of the spleen on the 
 T2-weighted images in  OsiriX
36.
Cellular thermal shift assay. The cellular thermal shift assay (CETSA) has been described  previously5. 
CETSA was performed on BL-41-luc cells from the xenografts frozen in  LN2. Vehicle treated mice were rand-
omized and then given karonudib (90 mg/kg) or vehicle both 18 h and 4 h before euthanization.
Microscopy. Hoechst stained cells from the flow cytometric cell cycle analysis were also prepared for micros-
copy using Cytospin as previously  described37.
Statistical testing. Statistical significance was determined by two-tailed unpaired Student’s t-test and one-
way ANOVA in addition to Log Rank test for the Kaplan–Meier plots in the animal studies. GraphPad Prism was 
used for calculations. Differences were considered to be significant if P < 0.05.
All experiments were approved and performed according to Institutional guideline of Oslo University Hospi-
tal. All experimental protocols using animals were approved by the Norwegian Food Safety Authority (Forsøks-
dyrsforvaltningens tilsyns og søknadssystem, FOTS), which is the licensing committee and the Department of 
Comparative Medicine, Oslo University Hospital, in compliance with the European Convention of the Protection 
of Vertebrates Used for Scientific Purposes (Project ID11675). Peripheral blood was obtained from anonymous, 
healthy donors at the Blood Bank (Oslo University Hospital, Norway), with informed consent and approval 
from regional authorities, Regional Ethical Committee for Medical and Health Research Ethics (REK S-03280) 
which is the licensing committee.
Results
To investigate the relevance of targeting MTH1 protein in B-cell lymphoma, we first investigated protein expres-
sion. MTH1 was highly expressed in B-cell lymphoma cells, while it was not detectable in activated peripheral 
blood B cells from healthy donors (Fig. 1A). Analysis of a published  dataset32 revealed increased expression of 
the NUDT1 mRNA in primary samples from patients with follicular lymphoma, diffuse large B-cell lymphoma 
and burkitt lymphoma (Fig. 1B). These data also demonstrated highest expression of NUDT1 in healthy donor 
germinal centre B cells, in particular centroblasts, whereas the mRNA expression was lower in naive and memory 
B cells. NUDT1 mRNA data were also obtained from the Leukemia Lymphoma Molecular Profiling Project 
(LLMPP)  datasets28–31, demonstrating significantly higher transcription level of NUDT1 in ABC and GCB DLBCL 
subtypes and in BL, but not in FL as compared to healthy donor B cells (Fig. 1C). These results indicate that 
MTH1 might be a rational target in aggressive B-cell lymphoma.
To test if karonudib had potent anti-lymphoma activity in vitro, a dose–response assay was performed in 
B-cell lymphoma cell lines representing ABC or GCB DLBCL, MCL and BL. Karonudib induced potent inhibi-
tory effect on cell growth in all lymphoma cell lines, with  IC50 ranging from 0.1 to 0.3 μM (Fig. 2A). In contrast, 
karonudib showed no effect on normal B cells from peripheral blood, activated with CD40L and IL-21 (Fig. 2A). 
In lymphoma cell lines, karonudib induced cell death determined by Propidium Iodide staining in a dose depend-
ent manner (Supplemental Fig. 1A). Detection of active caspase-3 after 24 h of karonudib treatment confirmed 
induction of apoptosis selectively in B-cell lymphoma cells, but not in normal B cells (Supplemental Fig. 1B).
Combination of viability staining with TUNEL assay demonstrated an increase in the fraction of TUNEL-
positive apoptotic cells after 12 h of karonudib treatment in three sensitive lymphoma cell lines, with a fur-
ther increase to > 50% apoptotic cells after 24 h (Fig. 2B, C). Few necrotic cells were detected (dead cell 
stain +  TUNEL−). Hence, apoptosis is the predominant form of cell death after karonudib treatment. The effect 
of karonudib on cell cycle distribution, cell cycle-resolved DNA damage and apoptosis was then studied in a time 
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dependent manner. Karonudib induced accumulation of cells in  G2 and particularly M phase for all three cell 
lines at 6 and 12 h after initiated treatment, while only the Mino cell line had a further increase in the percentage 
of  G2 and mitotic cells at 24 h (Fig. 2D). After 24 h treatment DoHH-2 was clearly-arrested in  G1 (Fig. 2D, E, red 
histograms). The apoptotic/dead cells (blue histograms) revealed that karonudib induced apoptotic cell death 
from the  G2/M phase in cell lines with mutant TP53 (Mino and BL-41, Supplemental Table 1), whereas DoHH-2 
(wt TP53) underwent apoptotic cell death also from  G1 phase (Fig. 2E, blue histograms). It was not possible to 
assess whether the apoptotic cells originated from  G2 or mitosis, as phospho-histone H3 expression is lost when 
mitotic cells become apoptotic (unpublished). The accumulated live cells were mainly mitotic cells as determined 
by phospho-histone H3 (ɣH2AX) expression (Supplemental Fig. 2B). Microscopic evaluation showed that the 
cells were arrested in prometaphase due to failure in spindle assembly, with formation of monopolar spindles and 
Figure 1.  MTH1 is upregulated in B-cell lymphoma cell lines and patient samples. (A) MTH1 protein 
expression in B-lymphoma cell lines and in normal B cells activated with CD40L/IL21 for 24 h (PBMCs, two 
donors; D1–D2). (B) NUDT1 mRNA data from microdissected samples from subpopulations of B cells from FL 
(n = 5), BL (n = 5) and DLBCL (n = 11) from Brune et al.32. (C) NUDT1 mRNA levels from the LLMPP-database: 
FL (n = 191), ABC-DLBCL (n = 176), GCB-DLBCL (n = 97), BL (n = 24), and B cells from PBMCs (n = 5). Stars 
represent significance compared to normal B cells.
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Figure 2.  Karonudib induces apoptosis after metaphase arrest in lymphoma cell lines, without affecting healthy 
B cells. (A) Cell viability was measured by CellTiterGlo and normalized to untreated samples (karonudib, 
0.0125–1 µM, 72 h, n = 3). (B) Gating strategy to identify apoptotic cells is shown for Mino cells (karonudib, 
0.5 µM, 24 h):  TUNEL+, light blue gate;, dead cells, dark blue gate; and live cells in red gate, and (C) the 
frequencies of these populations in Mino, BL-41 and DoHH-2 (karonudib, 0.5 µM, n = 3). (D) Cell cycle 
analyses of the live cells (from C). (E) Histograms representing live (red) and dead/apoptotic cells (blue) show 
 G2 accumulation and M-arrest after karonudib treatment. DoHH-2 also show a  G1 arrest at 24 h and cells 
entering apoptosis from  G1-arrest. (F) Microscopy of Hoechst stained cells from the same experiment in (B–E) 
(12 h with or without 0.5 µM karonudib, 63×/1.4 objective, bar = 10 µm). An error in the spindle assembly 
is clearly visible in cells treated with karonudib (images captured randomly), whereas images of successful 
chromosome segregation in control cells were chosen to illustrate the difference. (G) GSEA of BL-41 and Mino 
cells (karonudib, 0.5 µM, 12 h), identified Mitotic spindle and  G2/M-Checkpoint as significant altered gene sets 
(P < 0.001 and P = 0.006) (GSEA software v.3.0).
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lack of chromosome alignment on a metaphase plate (Fig. 2F). Cells in anaphase were not detected among the 
karonudib treated cells, in contrast to cells grown in the absence of karonudib (Fig. 2F). Together, this indicates 
that karonudib effectively blocked progression through mitosis. The arrest in prometaphase was not accompanied 
by increased levels of ɣH2AX (Supplemental Fig. 2C). DNA damage in S phase cells leads to increased replica-
tion stress and decreased DNA replication  rate22. However, karonudib did not increase ɣH2AX in S-phase cells 
(Supplemental Fig. 2C). Hence, karonudib does not increase the replication stress from the baseline levels, in 
contrast to what was observed with the PARP inhibitor  olaparib22. To find the transcriptomic changes induced by 
karonudib, gene expression profiling was performed of Mino and BL-41 cells treated with or without karonudib 
for 12 h. Gene set enrichment analysis was performed by combining the two cell lines for analysis, and revealed 
that only two gene sets were significantly dysregulated after karonudib treatment. These were gene sets anno-
tated as “mitotic spindle” and “G2/M arrest” (Fig. 2G; Supplemental Table 2 and Supplemental Fig. 3), which is 
in accordance with the results from the functional analysis by flow cytometry (Fig. 2D, E).
Karonudib inhibits the activity of MTH1, and also stabilizes the MTH1  protein5. To test if karonudib had 
a similar effect in normal and malignant B cells, the BL-41 and SU-DHL-6 cell lines and normal B cells were 
treated with karonudib for 6 and 18 h before preparing cell lysates and analysis of protein expression by West-
ern immunoblotting. This revealed that karonudib stabilized MTH1 in the B-cell lymphoma cells, but had no 
detectable effect in normal B cells (Fig. 3A). Drugs like karonudib that interfere with the MTH1 activity would 
be expected to increase the incorporation of 8-oxo-dGTP into DNA. This was indeed confirmed by the modified 
comet assay where BL-41 cells were treated with karonudib and the incorporation of 8-oxo-dGTP was analyzed 
indirectly by adding recombinant OGG-1 glycosylase (Fig. 3B, C, P < 0.001).
Because the specificity of the TH588 inhibitor has been  debated34,38, we generated NUDT1 knockout (KO) 
lymphoma cells using a Mino-Cas9 cell line. We successfully generated seven clones that lacked expression 
of MTH1 (Fig. 4A, Supplemental Fig. 4). Viability and proliferation assays showed an increased tolerance for 
karonudib in the NUDT1-KO clones (Fig. 4B, C). We selected two KO clones (KO1 and KO3) for further test-
ing to gain insight into the mechanisms of karonudib. Both NUDT1 KOs had significantly higher proliferation 
in the presence of karonudib as compared to wild type (WT) cells, demonstrating on-target effect of the drug 
(Fig. 4C). However, the KO cells were not completely resistant to karonudib, hence demonstrating additional 
MTH1-independent toxic effect of the drug. Cell cycle analysis demonstrated prominent accumulation in  G2 
and mitotic arrest in the two NUDT1-KO clones, similar to the WT cells after karonudib treatment (Fig. 4D, F). 
However, the two KO clones demonstrated increased resistance to karonudib induced apoptosis as compared 
to WT cells, with 68 and 65% live cells for NUDT1-KO1 and KO3 as compared to 37% live cells for WT cells 
when treated with 0.5 µM of karonudib (Fig. 4E, P < 0.0001). Cell cycle distribution was analyzed in the same 
experiments, and revealed that karonudib had similar effect on cell cycle arrest in the NUDT1-KO clones as in 
the WT cells (Fig. 4F). All together, these experiments demonstrate an on-target effect of karonudib for induc-
tion of apoptosis, whereas the cell cycle arrest is independent of MTH1 expression.
To test the efficacy of karonudib in vivo, the aggressive Burkitt lymphoma cell line BL-41-luc was inoculated 
subcutaneously in NSG mice, and in vivo luminescence was used to confirmed equal tumor load prior to treat-
ment (Supplemental Fig. 5A, B). For mice in the treatment group, karonudib was administered by oral gavage 
twice daily, 3 days a week over a period of 16 days. A significant decrease in tumor size in karonudib treated 
mice was observed from day 9 after treatment start (Fig. 5A, P < 0.0001). Imaging at day 13 showed a significant 
difference in tumor load between control and karonudib treated mice (Fig. 5B, P < 0.0001). However, about 
a week after end of treatment, tumor re-growth was observed. All mice eventually showed tumor re-growth, 
although at the end of study, three of the mice had tumor detectable by luminescence imaging only (Fig. 5A; 
Supplemental Fig. 5A). The survival curve showed a median time to end point of 14 versus 36 days for control 
and karonudib treated mice, respectively (Fig. 5C, P < 0.0001). To confirm target drug binding in vivo, a Cel-
lular Thermal Shift Assay (CETSA) was performed in tumors from mice treated with karonudib 24 h and 4 h 
before sampling (Fig. 5D). The melting curve obtained from the CETSA analysis demonstrated a thermal shift 
of 2.55 °C (P = 0.00012), indicating specific binding of karonudib to MTH1 in vivo. This indicated an on-target 
effect of karonudib upon in vivo treatment.
To further validate the preclinical effects of karonudib in B-cell lymphoma, we used a patient-derived lym-
phoma xenograft (PDX) model by intravenous injection of lymphoma cells from an ABC-DLBCL patient into 
NSG mice. This model demonstrated homing of tumor cells to the spleen and bone marrow, but with very few 
circulating tumor cells in the blood. Karonudib treatment was started 12 days after injection of tumor cells, and 
followed the same scheme as described for the BL-41 xenograft model, for a period of 23 days. The tumor growth 
was monitored by MR-imaging and volume measurement of the spleen. Also in the PDX model, karonudib 
demonstrated potent anti-lymphoma activity which was clearly shown by the lack of increased spleen size in 
the karonudib treated mice as long as they were under treatment (Fig. 6A; Supplemental Fig. 6A, B). MRI at 
day 18 after treatment start demonstrated massive infiltration of tumor cells in the spleen and bone marrow of 
the control mice, while karonudib treated mice had no sign of tumor cells (Fig. 6B; Supplemental Fig. 6A). The 
survival curve showed a median survival of 18 versus 28 days for control and karonudib treated mice, respectively 
(Fig. 6C, P < 0.0001). The MTH1 level in the karonudib treated group after tumor re-growth was unchanged 
compared to the control group (Supplemental Fig. 6C) suggesting that tumor cells after relapse still could be 
sensitive to karonudib treatment. Karonudib was generally well tolerated as demonstrated by similar weight 
distribution (Supplemental Fig. 6D). Taken together, karonudib was well tolerated and demonstrated potent 
anti-tumor activity in aggressive B-cell lymphoma preclinical models.
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Discussion
MTH1 inhibitors have demonstrated tumor suppressive properties in colon cancer, malignant melanoma, liver 
cancer, small cell lung cancer and breast cancer in mice  models5,15–18. However, the efficacy of MTH1 inhibitors 
in hematological malignancies has not yet been reported. In this first preclinical study of B-cell lymphoma, 
we demonstrate a strong inhibitory effect of karonudib on cell growth in a wide range of B-cell lymphoma cell 
lines at concentrations not affecting healthy donor normal B-cells. Karonudib mediated anti-lymphoma activ-
ity through induction of mitotic arrest, leading to apoptosis. Testing of NUDT1 KO clones revealed that the 
Figure 3.  Inhibition of MTH1 leads to increased incorporation of 8-oxo-dGTP. (A) MTH1 expression was 
detected in total cell lysates (karonudib, 0.5 µM, 6 h, 18 h). (B, C) A modified comet assay was used to indirectly 
measure incorporation of 8-oxo-dGTP. An increase in comet tails indicates nick in the DNA by recombinant 
8-oxoguanin-DNA-glycosylase (OGG-1) where 8-oxo-dGTP is present. BL-41 cells (karonudib, 0.5 µM, 24 h. 
 KBrO3 was used as a positive control (n = 200)). Images are acquired by Zeiss IF microscope and quantified 
using Comet Assay IV software.
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Figure 4.  NUDT1 KO in Mino cell lines confirm dual mechanism of karonudib. Two NUDT1 KO clones 
of Mino were used to assess the effect of MTH1 loss in the lymphoma model. (A) Western immunoblot 
of seven clones show loss of MTH1 expression. (B) Cell viability was measured in Mino WT (green) and 
NUDT1 KO (orange) by CellTiterGlo and normalized to untreated samples (karonudib, 0.0125–1 µM, 72 h, 
n = 3) (C) Proliferation using Cell Trace Violet (CTV) is shown for Mino WT, NUDT1 KO1 and NUDT1 KO3 
(continuous line: control cells at time zero, dashed line: control 72 h and filled histogram: 0.25 µM karonudib 
72 h). Quantification of the % (shown in gate) of proliferating cells in WT and 0.25 µM karonudib treated cells. 
*Significant differences (P < 0.05), repeated measurements one-way ANOVA with Dunetts correction between 
WT and the KO-clones. (D) Gating strategy to identify live, dead and apoptotic cells is shown for Mino cells in 
Fig. 2B. Histogram representing live (red) and dead/apoptotic cells (blue) show  G2 accumulation and M-arrest 
after karonudib treatment, 24 h. (E)  TUNEL+, light blue,; dead cells, dark blue,; and live cells in red show the 
frequencies of these populations in Mino WT, NUDT1 KO 1 and NUDT1 KO 3 (karonudib, 0.25 and 0.5 µM, 
24 h, n = 3). *Significant differences (P < 0.0001, one-way ANOVA with Dunetts correction) between WT and 
the KO-clones for both concentrations of karonudib. (F) Cell cycle analyses of the live cells from (E).
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apoptosis-induced effect of karonudib partially was mediated by MTH1, whereas the cell cycle arrest was an 
MTH1-independent effect. We further demonstrated potent anti-tumor efficacy of karonudib in vivo in two 
different lymphoma xenograft models, including an ABC DLBCL PDX xenograft model.
MTH1 was highly expressed in B-cell lymphoma cell lines compared to normal activated B cells, and was 
therefore identified as a potential target. Based on this information and the fact that MTH1 has been charac-
terized as a non-essential protein in normal cells within a realistic treatment  window39, we hypothesized that 
patients with B-cell lymphoma could possibly benefit from inhibition of MTH1. Analysis of publicly available 
gene expression data have shown that the NUDT1 expression increases with proliferation status of the B-cell 
 subtype11, and is in concordance with the known high tumor cell proliferation rate in these subtypes. In mice, 
depletion of MTH1 seemed not to affect their health as MTH1 knockout mice appear healthy and have survival 
rates comparable to normal  mice10. The human toxicity profile will be addressed in the on-going first in human, 
first in class phase I clinical trials with karonudib monotherapy in advanced cancer patients (NCT03036228 and 
NCT04077307 at https:// clini caltr ials. gov).
Karonudib has previously been shown to specifically bind to  MTH15, and exposure leads to elevated incor-
poration of oxidized nucleotides into DNA. This effect could be reversed by overexpressing MTH1, MutT (the 
bacterial version of MTH1) or by pretreatment with ROS  scavenger7. Here, we demonstrated direct binding of 
karonudib to MTH1 in mice. Although all mice treated with karonudib eventually relapsed, the level of MTH1 
Figure 5.  Karonudib has a strong anti-tumor effect in vivo. (A) Tumor growth of BL-41-luc cells was monitored 
with IVIS luminescence measurements (physical units of surface radiance (photons/s/cm2/st)) at day 0, 9, 13, 
17, 23, 29 and 36 after treatment start. Treatment was initiated 6 days after inoculation, and karonudib was given 
per os, b.i.d, 90 mg/kg three times a week for 16 days. Tumor growth was significantly decreased in mice treated 
with karonudib already at day 9, 13 and 17 compared with treatment start (P < 0.0001 for all time points). There 
was a significant difference (P < 0.0001) between treatment and vehicle both 9 and 13 days after treatment start 
(unpaired two-tailed t-test with Welsh’s correction). (B) IVIS image of animals at day 13. (C) Kaplan–Meier is 
based on tumor size (> 2  cm3 or 2 cm length in one direction). Median survival was 14 vs. 36 days in control 
vs. karonudib treated mice (P < 0.0001, Log-rank test). Arrow indicates end of treatment. (D) In vivo target 
engagement of karonudib to MTH1 shown by CETSA. Vehicle treated mice were randomized and then given 
karonudib (90 mg/kg) or vehicle 18 h and 4 h prior to euthanization and dissection of tumor tissue. Melting 
curve for MTH1 with a significant  Tm shift of 2.55°C is shown (P = 0.00012, karonudib treated (n = 5), vehicle 
(n = 6)) measured at 50% MTH1 denaturation.
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remained similar to the before-treatment level. This suggests that tumor cells after relapse still could be sensitive 
to karonudib.
Figure 6.  Karonudib has a strong anti-tumor effect in the ABC DLBCL PDX model DFBL-49659-V2. Tumor 
cells were injected intravenously and tumor growth monitoring of spleen and bone marrow with MR-imaging. 
(A) The treatment was initiated 12 days after tumor injection, and continued for 23 days as indicated (karonudib 
per os, b.i.d, 90 mg/kg three times a week). Spleen volume was measured by manual delineation on the  T2-
weighted images. First scan was performed 4 days prior to treatment start up. (B)  T2-weighted MRI scans of 
a karonudib and vehicle treated mice at day 18. The arrows indicate increased spleen and edema around the 
spine in the untreated animal. (C) Median survival was 18 vs. 38 days in control vs. karonudib treated mice 
(P < 0.0001, Log-rank test). The mice were monitored until they showed clinical signs. Arrow indicates end of 
treatment. All images are presented in Supplemental Fig. 6A.
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Here, we demonstrated that all B-cell lymphoma cell lines displayed a pronounced mitotic arrest in response 
to karonudib treatment, due to aberrant mitotic spindle formation. This may be related to the mechanism of 
action of karonudib, targeting  microtubuli13. The transcriptional changes induced by karonudib in lymphoma 
cell lines supports this hypothesis as the only significant enrichment profiles identified were "spindle formation" 
and "G2/M-arrest". In addition to mitotic arrest in all three tested lymphoma cell lines, the TP53 mutation status 
influenced the type of cell cycle arrest induced. Whereas karonudib induced  G2/M arrest in cell lines harboring 
mutant TP53, DoHH-2 with WT TP53 additionally had a pronounced  G1 arrest after karonudib treatment. Our 
finding that karonudib had potent inhibitory effect in lymphoma cells harboring mutated TP53 could be an 
important discovery, as many drugs used in treatment of relapsed lymphoma patients require a functional TP53 
to be  effective40–42 and TP53 loss or mutation is associated with inferior  survival42–45. Furthermore, karonudib 
was also potent in lymphoma cells regardless of the mutational or translocation status of MYC (Supplemental 
Table 1). This is essential since double-hit lymphomas with aberrant expression of MYC and BCL2 has dismal 
 outcome46,47. Further studies to evaluate therapeutic effect of karonudib in B-cell lymphoma subtypes including 
high-risk patients are therefore warranted.
However, the validity of MTH1 and MTH1 inhibitors in cancer has been debated and TH588, the first gen-
eration MTH1 inhibitor, has been shown to bind microtubuli and induce mitotic arrest in MTH1 knockout cell 
 lines34,38. Additional mechanism of action has been proposed for the cytotoxic MTH1 inhibitors and indeed karo-
nudib has a dual mechanism of action. Karonudib causes mitotic arrest via disturbed microtubule polymerization 
and increased oxidized nucleotides incorporated into DNA during  mitosis13. Interestingly, the non-cytotoxic 
MTH1 inhibitors can become cytotoxic and elevate incorporation of oxidized nucleotides into DNA when 
combined with a mitotic arrest compound such as paclitaxel, CENP-E  inhibitor13, supporting the importance 
of having a dual mechanism for effective anti-tumor effect. Based on this, we hypothesized that karonudib and 
TH588 have dual mechanism of action in tumor cells by inhibition of spindle formation during mitosis leading 
to mitotic arrest, and by inducing increased levels of oxidized nucleotides and increased incorporation of 8-oxo-
dGTP in the  genome14. That drugs have different mechanism of action is however common, even for drugs that 
have entered clinical  trials48. Since this has implications for efficacy and toxicity in patients, it calls for stringent 
genetic validation of action for cancer drugs in the preclinical setting. We generated NUDT1 KO clones and test-
ing the effect of karonudib. In these clones we demonstrated on-target effect as the apoptosis-inducing effect to 
the drug was partially lost upon loss of MTH1. However, since NUDT1 KO clones exhibited a similar cell cycle 
arrest phenotype as the WT cells after karonudib treatment, this clearly shows that karonudib can induce cell 
cycle arrest independent of MTH1, and hence has a dual mechanism of action (Fig. 7).
Taken together, our data suggest that karonudib is a new promising drug with a potential broad therapeutic 
use in B-cell lymphoma. The drug has a dual mechanism of action and may be particular effective in aggressive 
lymphoma with both high MTH1 levels and high proliferation rate.
Data availability
Microarray data is available at NCBI’s Gene Expression Omnibus with accession number GSE123449.
Figure 7.  Dual mechanism of karonudib leads to apoptosis in lymphoma cells. Karonudib was developed 
to target the nucleotide metabolism by inhibiting the nucleotide pool sanitizing enzyme, MTH1. MTH1 
converts oxidized nucleotide triphosphates created by reactive oxygen species (ROS) to the corresponding 
monophosphate forms, preventing incorporation of oxidized nucleotides into DNA. High ROS levels in 
lymphoma corresponds to high MTH1 levels. Karonudib inhibits the function of MTH1 and results in increased 
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